| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation M Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, ... New England Journal of Medicine 377 (6), 523-533, 2017 | 3192 | 2017 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3091 | 2017 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ... The Lancet 376 (9737), 235-244, 2010 | 2193 | 2010 |
| Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation ND Kauff, JM Satagopan, ME Robson, L Scheuer, M Hensley, CA Hudis, ... New England Journal of Medicine 346 (21), 1609-1615, 2002 | 1688 | 2002 |
| Inherited DNA-repair gene mutations in men with metastatic prostate cancer CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ... New England Journal of Medicine 375 (5), 443-453, 2016 | 1675 | 2016 |
| Gene-panel sequencing and the prediction of breast-cancer risk DF Easton, PDP Pharoah, AC Antoniou, M Tischkowitz, SV Tavtigian, ... New England Journal of Medicine 372 (23), 2243-2257, 2015 | 1041 | 2015 |
| Polygenic risk scores for prediction of breast cancer and breast cancer subtypes N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ... The American Journal of Human Genetics 104 (1), 21-34, 2019 | 991 | 2019 |
| Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group F Mosele, J Remon, J Mateo, CB Westphalen, F Barlesi, MP Lolkema, ... Annals of Oncology 31 (11), 1491-1505, 2020 | 990 | 2020 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 848 | 2018 |
| A note on competing risks in survival data analysis JM Satagopan, L Ben-Porat, M Berwick, M Robson, D Kutler, ... British journal of cancer 91 (7), 1229-1235, 2004 | 808 | 2004 |
| Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) N Mavaddat, D Barrowdale, IL Andrulis, SM Domchek, D Eccles, ... Cancer Epidemiology, Biomarkers & Prevention 21 (1), 134-147, 2012 | 792 | 2012 |
| ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ... Annals of oncology 32 (12), 1475-1495, 2021 | 783 | 2021 |
| Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ... Cell stem cell 21 (3), 374-382. e4, 2017 | 730 | 2017 |
| Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study ND Kauff, SM Domchek, TM Friebel, ME Robson, J Lee, JE Garber, ... Journal of clinical oncology 26 (8), 1331-1337, 2008 | 719 | 2008 |
| OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2 … ME Robson, N Tung, P Conte, SA Im, E Senkus, B Xu, N Masuda, ... Annals of Oncology 30 (4), 558-566, 2019 | 714 | 2019 |
| Prediction of breast cancer risk based on profiling with common genetic variants N Mavaddat, PDP Pharoah, K Michailidou, J Tyrer, MN Brook, MK Bolla, ... Journal of the National Cancer Institute 107 (5), djv036, 2015 | 691 | 2015 |
| Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study SA Narod, JS Brunet, P Ghadirian, M Robson, K Heimdal, SL Neuhausen, ... The Lancet 356 (9245), 1876-1881, 2000 | 687 | 2000 |
| Genetic/familial high-risk assessment: breast and ovarian MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ... Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010 | 685* | 2010 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 660 | 2013 |
| American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility ME Robson, AR Bradbury, B Arun, SM Domchek, JM Ford, HL Hampel, ... Journal of Clinical Oncology 33 (31), 3660-3667, 2015 | 605 | 2015 |
Kenneth OffitMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
